Replies to post #2138 on Iterum Therapeutics (ITRM)

[MasterBlastr]

The one analyst covering this stock has a $15 target. I'd say more like $40 but they do have to rerun a Phase 3 comparing it with another known drug. Hopefully this will go fairly quickly. Women's urinary tract infections is a huge market.